My Blue Dots

CAMBRIDGE, Mass.–(BUSINESS WIRE)–MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced the in-licensing of a next-generation selective PARP1 (poly ADP-ribose polymerase) inhibitor, now known as MOMA-989. The company also provided an update on the clinical progress of Polθ inhibitor MOMA-313 and outlined the clinical path for Werner inhibitor MOMA-341. “The addition of this selective PARP1 inhibitor

WALTHAM, Mass.–(BUSINESS WIRE)–MDaudit, a premier provider of billing, coding compliance and revenue integrity software for health systems, hospitals, and provider groups, announced a strategic growth investment from Bregal Sagemount (“Sagemount”), a leading growth-focused private equity firm, and Primus Capital (“Primus”), the company’s existing investor. Terms of the transaction were not disclosed. MDaudit, headquartered in Waltham, MA, specializes in delivering high-quality, customer-centr

WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announces the company’s key priorities and catalysts for 2025. “After a great year of execution across the portfolio, we enter 2025 poised to deliver on a number of important catalysts,” said Steve Mahoney, Viridian’s President and CEO. “We believe that the positive and better-than-expect

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2024 at 8:15 a.m. PT in San Francisco, CA. A live webcast of the event will be accessible by visiting the “Events and Present

RALEIGH, N.C. & OKLAHOMA CITY–(BUSINESS WIRE)–Lumata Health, a technology-driven healthcare innovator empowering ophthalmology practices to enhance continuous care for those at risk of blindness from chronic eye diseases, today formally announced its Clinical Advisory Board (CAB). The esteemed group of five leading ophthalmologists will provide strategic guidance to further Lumata’s mission of reducing preventable blindness through its turnkey, patient-centered continuous care platform. The C

SYRACUSE, N.Y.–(BUSINESS WIRE)– #ClinicalTrials–Central New York Biotech Accelerator (CNYBAC). -– Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing proprietary carriers delivering tumoricidal therapies for metastatic and primary breast cancer, which may minimize patient side effects with the potential to increase survival rates, announced today in 2024 they nearly doubled their worldwide IP portfolio to 64 patents, spanning across 36 countries including the

HOUSTON–(BUSINESS WIRE)–SynergenX Health and HerKare, two leading providers of hormone therapy and wellness services, are raising awareness about the life-changing benefits of testosterone replacement therapy (TRT) for women. Over the past decade, testosterone prescriptions have increased by almost 50% in the United States alone. Testosterone, often associated with men, is vital for women’s health, playing a key role in energy, mood, libido, and muscle maintenance. As women age, testosterone

RAHWAY, N.J.–(BUSINESS WIRE)—- $MRK #MRK–Merck’s GARDASIL® Receives Expanded Approval for Males in China

ATLANTA–(BUSINESS WIRE)–UPS (NYSE: UPS) today announced that it has completed the acquisition of Frigo-Trans and its sister company BPL, which provide industry-leading, complex healthcare logistics solutions across Europe. The acquisitions further enhance the end-to-end capabilities available to UPS Healthcare customers, who increasingly need temperature-controlled and time-critical logistics solutions globally. Frigo-Trans’ network includes temperature-controlled warehousing ranging from cry

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sage Therapeutics, Inc. (NASDAQ: SAGE) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 8:15 a.m. PT in San Francisco, CA. A live webcast of the presentation can be accessed on the Investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutic